TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Denmark suspends use of AstraZeneca vaccine over blood clot fears

The move comes "following reports of serious cases of blood clots among people vaccinated with AstraZeneca's Covid-19 vaccine", the Danish Health Authority said in a statement. 

News Desk (Agence France-Presse)
Copenhagen, Denmark
Thu, March 11, 2021 Published on Mar. 11, 2021 Published on 2021-03-11T17:23:19+07:00

Change text size

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
In this file photo taken on January 09, 2021 boxes of vials of the Oxford/AstraZeneca Covid-19 vaccine are seen in a refridgerator at Ashton Gate Stadium in Bristol, one of seven mass vaccination centres which are set to open next week as Britain continues its vaccination programme against Covid-19. D In this file photo taken on January 09, 2021 boxes of vials of the Oxford/AstraZeneca Covid-19 vaccine are seen in a refridgerator at Ashton Gate Stadium in Bristol, one of seven mass vaccination centres which are set to open next week as Britain continues its vaccination programme against Covid-19. D (Agence France Presse/Andrew Matthews)

D

anish health authorities said Thursday they were temporarily suspending the use of AstraZeneca's Covid-19 vaccine as a precaution after some patients developed blood clots since receiving the jab.

The move comes "following reports of serious cases of blood clots among people vaccinated with AstraZeneca's Covid-19 vaccine", the Danish Health Authority said in a statement. 

But it cautiously added that "it has not been determined, at the time being, that there is a link between the vaccine and the blood clots".

Earlier on Wednesday, Europe's medicines watchdog said a preliminary probe showed that a batch of AstraZeneca vaccines used in Austria was likely not to blame for the death of a nurse who received a jab.

Austria on Monday announced it would stop using doses from the batch, made by the British-Swedish firm with Oxford University, after the 49-year-old nurse died of "severe blood coagulation problems" days after receiving an anti-Covid shot.

A second woman was also hospitalised after developing a pulmonary embolism and was now recovering, the European Medicines Agency said. 

Two other reports of "thromboembolic event cases had been received for this batch," the Amsterdam-based EMA said.

However "there is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine," it said in a statement.

Four other EU countries -- Estonia, Latvia, Lithuania and Luxembourg -- have also suspended vaccinations from this batch, sent to 17 European countries and consisting of one million jabs.

"Although a quality defect is considered unlikely at this stage, the batch quality is being investigated," the EMA said.

Since inoculation campaigns began in earnest, isolated cases have been reported in some countries of people dying shortly after receiving a vaccine.

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.

Share options

Quickly share this news with your network—keep everyone informed with just a single click!

Change text size options

Customize your reading experience by adjusting the text size to small, medium, or large—find what’s most comfortable for you.

Gift Premium Articles
to Anyone

Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!

Continue in the app

Get the best experience—faster access, exclusive features, and a seamless way to stay updated.